NeuroSense (NRSN) CTO awarded 200,000 restricted shares vesting over two years

NodeGuardian · 2026-04-10T16:56:39+00:00

NeuroSense Therapeutics CTO Niva Russek-Blum received 200,000 restricted shares as compensation, vesting quarterly over two years starting March 2026, contingent on continued service. This increases her holdings to 467,953 shares and is subject to Israeli tax benefits.

NodeGuardian

2026-04-10 16:56:39

Abstract generation in progress

NeuroSense Therapeutics Ltd. (NRSN) Chief Technology Officer Niva Russek-Blum was granted 200,000 restricted Ordinary Shares as compensation. These shares, with a stated price of $0.00 per share, will vest in equal quarterly installments over a two-year period beginning March 26, 2026, contingent on her continued service. This grant increases her direct holdings to 467,953 Ordinary Shares and is subject to Section 102 of the Israeli Tax Ordinance for certain tax benefits.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.